NCT00669591 2017-04-21
A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer
Peregrine Pharmaceuticals
Phase 2 Completed
Clinical Trials
3 trialsNCT02685306 2017-03-09
A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer
Peregrine Pharmaceuticals
Phase 2 Withdrawn
NCT00669565 2011-03-24
Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer
Peregrine Pharmaceuticals
Phase 2 Completed